Oppenheimer cuts Dyne Therapeutics target to $15 from $40

Oppenheimer downgraded Dyne Therapeutics's stock to Perform with a price target of $15.00.The price target implies a downside of 11.5% from the Oct 27 close of $16.94.Key takeaways from the analyst noteConcerns Over Trial Size and Power: Dyne Therapeutics' decision to maintain a small trial size of…